A5055564981- Migraine and Headache Studies
- Olfactory and Sensory Function Studies
- Healthcare Policy and Management
- Emergency and Acute Care Studies
- Pharmacological Effects and Toxicity Studies
- Cardiovascular Syncope and Autonomic Disorders
- Trigeminal Neuralgia and Treatments
- Innovations in Medical Education
- Respiratory and Cough-Related Research
- Psychosomatic Disorders and Their Treatments
- Spinal Fractures and Fixation Techniques
- Congenital Diaphragmatic Hernia Studies
- Pain Management and Placebo Effect
- Epilepsy research and treatment
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Traumatic Brain Injury and Neurovascular Disturbances
- Service-Learning and Community Engagement
- Airway Management and Intubation Techniques
- Cardiac electrophysiology and arrhythmias
- Botulinum Toxin and Related Neurological Disorders
- COVID-19 Clinical Research Studies
- Tracheal and airway disorders
- Bipolar Disorder and Treatment
- Healthcare Operations and Scheduling Optimization
- Simulation-Based Education in Healthcare
Biohaven Pharmaceuticals (United States)
2019-2024
John Wiley & Sons (United States)
2023
Hudson Institute
2023
University of California, Davis
2013-2022
University College London Hospitals NHS Foundation Trust
2020
University College London
2020
University of California Davis Medical Center
2009-2014
Bristol-Myers Squibb (United States)
2011
Hamilton Health Sciences
2000-2010
Loughborough University
2007
Calcitonin gene-related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin antagonist that may be effective acute migraine treatment.In a multicenter, double-blind, phase 3 trial, we randomly assigned adults with at least 1-year history and two to eight attacks moderate or severe intensity per month receive rimegepant dose 75 mg matching placebo for treatment single attack. The primary end points were freedom...
Background Other than aspirin, there are few oral antithrombotic treatments with proven efficacy in patients acute coronary syndrome. In this report, we present the rationale, design and baseline characteristics of Clopidogrel Unstable angina to prevent Recurrent ischaemic Events (CURE) trial, which includes a meta-analysis effects thienopyridines vascular disease.
Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, Sanchez R. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment patients with bipolar I disorder an inadequate response monotherapy: a multicenter, double-blind, randomized study.Bipolar Disord 2011: 13: 133–144. © 2011 The Authors.Journal compilation John Wiley & Sons A/S. Listen interview article author Objectives: To evaluate efficacy and safety (ARI) (Li) (Val) (ARI + Li / Val) compared placebo...
This post-hoc analysis from three phase 3 treatment trials of rimegepant 75 mg - an oral small molecule calcitonin gene-related peptide receptor antagonist for acute and preventive migraine assessed efficacy in adults with based on triptan experience.Participants were assigned to one four groups experience: insufficient response (e.g. lack and/or poor tolerability) 1 triptan, ≥2 triptans, current users, triptan-naïve participants. The co-primary endpoints pain freedom most bothersome symptom...
In this study, a discrete-event simulation approach was used to model Emergency Department's (ED) patient flow investigate the effect of inpatient boarding on ED efficiency in terms National Department Crowding Scale (NEDOCS) score and rate patients who leave without being seen (LWBS). The decision variable boarder-released-ratio defined as ratio admitted whose time is zero all patients. Our analysis shows that Overcrowded(+) (a NEDOCS over 100) decreased from 88.4% 50.4%, LWBS 10.8% 8.4%...
Zavegepant is a novel gepant administered as nasal spray approved in the United States at 10 mg dose for acute treatment of migraine with or without aura adults. The cardiovascular safety zavegepant was assessed both single-ascending (SAD) and multiple-ascending (MAD) studies healthy participants. SAD study included 72 participants (54 active/18 placebo) who received 0.1-40 placebo. MAD (56 active/16 5-40 placebo 1-14 days. Plasma pharmacokinetics electrocardiographic (ECG) parameters...
Background Rimegepant is an oral, small molecule calcitonin gene-related peptide receptor antagonist for acute treatment of migraine and prevention. Methods This was a single-site, placebo-controlled, sequential, single multiple ascending dose study in healthy males females, aged 18–55 years, with no clinically significant medical history. The objectives were to assess the safety, tolerability, pharmacokinetics oral capsule free-base formulation. Single doses rimegepant from 25–1500 mg...
A single-center, phase I, partially double-blind (double-blind regarding doses of rimegepant and placebo, open label with respect to moxifloxacin), randomized, 12-sequence, four-period crossover study therapeutic (75 mg) supratherapeutic (300 placebo moxifloxacin (400 controls was designed evaluate drug effect on the Fridericia corrected QT (QTcF) interval in healthy fasted adults. total 38 participants were randomized dosed study. Electrocardiogram (ECG) data available from 37 75-mg group,...
Abstract Zavegepant, a high‐affinity, selective, small‐molecule calcitonin gene‐related peptide (CGRP) receptor antagonist, is approved in the United States for acute treatment of migraine adults. The effects moderate hepatic impairment (8 participants with Child‐Pugh score 7–9 points) on pharmacokinetics single 10‐mg intranasal dose zavegepant versus eight matched normal function were evaluated phase I study. Pharmacokinetic sampling determined total and unbound plasma concentrations....
The aim of this study was to determine the extent which resistance provided by variable-cam training machines match joint torque capability. Eight knee extension from six different manufacturers were assessed. Resistive for a constant weight/load measured at five angles. Knee extensor muscle capability--the angle-torque relationship--of 10 healthy young men determined isometrically and dynamically same After normalization, two relationships compared. angle - relationship extensors displayed...
Rimegepant is a small-molecule calcitonin gene-related peptide receptor antagonist (gepant) with demonstrated efficacy and safety in the acute preventive treatment of migraine. Here, we report pharmacokinetics single 75-mg oral dose rimegepant subjects severe, moderate, or mild hepatic impairment matched healthy from an open-label, single-dose, 4-group phase 1 study. Thirty-six aged 41-71 years were enrolled, including 6 each 18 subjects. All completed A <20% increase total unbound was...
To assess the effect of single and multiple doses rimegepant 75 mg dose on pharmacokinetics an oral contraceptive containing ethinyl estradiol (EE)/norgestimate (NGM) in healthy females childbearing potential or non-menopausal with tubal ligation.Females age experience highest prevalence migraine frequently inquire about concomitant use anti-migraine medications contraceptives. Rimegepant, a calcitonin gene-related peptide receptor antagonist, demonstrated efficacy safety for treating acute...
<h3>Objective:</h3> Evaluate co-administration of zavegepant+sumatriptan on resting blood pressure (BP); pharmacokinetics (PK) sumatriptan and zavegepant alone combined; effects BP vs placebo; safety tolerability in healthy participants. <h3>Background:</h3> Zavegepant (BHV-3500; formerly vazegepant) is a high-affinity, selective, small-molecule CGRP receptor antagonist development for migraine. <h3>Design/Methods:</h3> In Phase 1, single-center, randomized, partially blind,...
Abstract Rimegepant is a calcitonin gene‐related peptide receptor antagonist approved for migraine treatment. This phase 1, open‐label, single‐center, fixed‐sequence study evaluated the effect of rimegepant on pharmacokinetics (PK) metformin. Twenty‐eight healthy participants received metformin 500 mg twice daily from Days 1 to 4 and 7 10, once 5 11. Rimegepant, 75 tablet, was administered 9 12. At pre‐specified time points, plasma concentration, serum glucose levels, safety tolerability...
In Brief Clinicians' ability to be assertive when unsure or concerned about procedures, treatment modalities, patients' symptoms is key in reducing risk and preventing sentinel events. this article, the authors provide a framework for generic, voluntary assertiveness communication skills workshops that any educator can implement. The describe an workshop developed advance patient safety culture.
Questions surround the appropriate emergency department (ED) disposition of children who have sustained blunt head trauma (BHT). Our objective was to identify physician preferences with (BHT) and varying computed tomography (CT) findings.WE SURVEYED PEDIATRIC AND GENERAL EMERGENCY PHYSICIANS (EP), NEUROSURGEONS (PNSURG), (GNSURG), SURGEONS (PSURG) TRAUMA REGARDING CARE OF TWO HYPOTHETICAL PATIENTS: Case 1: a 9-year-old fell 10 feet 2: an 11-month-old 5 feet. We presented various CT findings...
Health services delivery is increasingly shifting to community-based settings. The competencies required of future health professionals require a shift in their educational preparation. Service learning suggested as an method with the potential reform professions education tandem changes occurring delivery. Professions Schools Nation Program (HPSISN), US demonstration project service professions, examines impact on students, faculty, communities and institutions across wide array...
Introduction: Questions surround the appropriate emergency department (ED) disposition of children who have sustained blunt head trauma (BHT). Our objective was to identify physician preferences with (BHT) and varying computed tomography (CT) findings.Methods: We surveyed pediatric general physicians (EP), neurosurgeons (PNSurg), (GNSurg), surgeons (PSurg) regarding care two hypothetical patients: Case 1: a 9-year-old fell 10 feet 2: an 11-month-old 5 feet. presented various CT findings...
Abstract Zavegepant is a calcitonin gene‐related peptide receptor antagonist for acute migraine treatment. This Phase I, open‐label, fixed‐sequence study evaluated the effects of itraconazole (a strong cytochrome P450 3A4 [CYP3A4] and P‐glycoprotein [P‐gp] inhibitor) on pharmacokinetics intranasal/oral zavegepant rifampin inducer CYP3A4 P‐gp; an inhibitor organic anion transporting polypeptide 1B3 [OATP1B3]) oral in healthy participants. In zavegepant–itraconazole cohort, participants...
Assess the efficacy of rimegepant in subjects with a history treatment failure 1 or ≥2 serotonin 5-HT1B/1D receptor agonists (triptans).
Abstract Objective Reported here are the results of four rimegepant phase I studies, in healthy participants, aimed at determining vivo potential (75 mg) for cytochrome P450 (CYP) 3A4‐related drug–drug interactions (DDIs). Background Rimegepant orally disintegrating tablet (Pfizer Inc., New York, NY, USA) is a calcitonin gene‐related peptide receptor antagonist approved acute treatment migraine and preventive episodic migraine. People with commonly use multiple drug treatments, DDIs. Methods...
Compare the efficacy of rimegepant with placebo in acute treatment migraine among patients who discontinued or currently use 5-HT1B/1D agonists (triptans).